184 related articles for article (PubMed ID: 28883001)
1. KDM4 Inhibition Targets Breast Cancer Stem-like Cells.
Metzger E; Stepputtis SS; Strietz J; Preca BT; Urban S; Willmann D; Allen A; Zenk F; Iovino N; Bronsert P; Proske A; Follo M; Boerries M; Stickeler E; Xu J; Wallace MB; Stafford JA; Kanouni T; Maurer J; Schüle R
Cancer Res; 2017 Nov; 77(21):5900-5912. PubMed ID: 28883001
[TBL] [Abstract][Full Text] [Related]
2. EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency.
Fu W; Lei C; Yu Y; Liu S; Li T; Lin F; Fan X; Shen Y; Ding M; Tang Y; Ye X; Yang Y; Hu S
Clin Cancer Res; 2019 May; 25(9):2835-2847. PubMed ID: 30670492
[TBL] [Abstract][Full Text] [Related]
3. GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells.
Yan N; Xu L; Wu X; Zhang L; Fei X; Cao Y; Zhang F
Exp Cell Res; 2017 Oct; 359(2):405-414. PubMed ID: 28823831
[TBL] [Abstract][Full Text] [Related]
4. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
5. MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.
Yang A; Qin S; Schulte BA; Ethier SP; Tew KD; Wang GY
Cancer Res; 2017 Dec; 77(23):6641-6650. PubMed ID: 28951456
[TBL] [Abstract][Full Text] [Related]
6. JMJD3 suppresses stem cell-like characteristics in breast cancer cells by downregulation of Oct4 independently of its demethylase activity.
Xun J; Wang D; Shen L; Gong J; Gao R; Du L; Chang A; Song X; Xiang R; Tan X
Oncotarget; 2017 Mar; 8(13):21918-21929. PubMed ID: 28423536
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
[TBL] [Abstract][Full Text] [Related]
8. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
9. Histone demethylase KDM7A is required for stem cell maintenance and apoptosis inhibition in breast cancer.
Meng Z; Liu Y; Wang J; Fan H; Fang H; Li S; Yuan L; Liu C; Peng Y; Zhao W; Wang L; Li J; Feng J
J Cell Physiol; 2020 Feb; 235(2):932-943. PubMed ID: 31236965
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness.
Lan J; Wei G; Liu J; Yang F; Sun R; Lu H
Theranostics; 2022; 12(6):2598-2612. PubMed ID: 35401817
[No Abstract] [Full Text] [Related]
11. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
12. The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.
Yu F; Zhao J; Hu Y; Zhou Y; Guo R; Bai J; Zhang S; Zhang H; Zhang J
Oncol Rep; 2016 Jul; 36(1):356-64. PubMed ID: 27175939
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
[TBL] [Abstract][Full Text] [Related]
14. KDM4B-regulated unfolded protein response as a therapeutic vulnerability in
Wang W; Oguz G; Lee PL; Bao Y; Wang P; Terp MG; Ditzel HJ; Yu Q
J Exp Med; 2018 Nov; 215(11):2833-2849. PubMed ID: 30266800
[No Abstract] [Full Text] [Related]
15. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
16. Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.
Iskit S; Lieftink C; Halonen P; Shahrabi A; Possik PA; Beijersbergen RL; Peeper DS
Oncotarget; 2016 Jul; 7(28):42859-42872. PubMed ID: 27374095
[TBL] [Abstract][Full Text] [Related]
17. Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
Zheng Q; Fan H; Meng Z; Yuan L; Liu C; Peng Y; Zhao W; Wang L; Li J; Feng J
Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):897-904. PubMed ID: 30060056
[TBL] [Abstract][Full Text] [Related]
18. Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.
Lin CC; Lo MC; Moody R; Jiang H; Harouaka R; Stevers N; Tinsley S; Gasparyan M; Wicha M; Sun D
Cancer Lett; 2018 Dec; 438():165-173. PubMed ID: 30227220
[TBL] [Abstract][Full Text] [Related]
19. ADAM protease inhibition overcomes resistance of breast cancer stem-like cells to γδ T cell immunotherapy.
Dutta I; Dieters-Castator D; Papatzimas JW; Medina A; Schueler J; Derksen DJ; Lajoie G; Postovit LM; Siegers GM
Cancer Lett; 2021 Jan; 496():156-168. PubMed ID: 33045304
[TBL] [Abstract][Full Text] [Related]
20. Wnt/β-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells.
Jang GB; Hong IS; Kim RJ; Lee SY; Park SJ; Lee ES; Park JH; Yun CH; Chung JU; Lee KJ; Lee HY; Nam JS
Cancer Res; 2015 Apr; 75(8):1691-702. PubMed ID: 25660951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
